Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase I/Ib Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction GEJ Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumor Have Claudin CLDN 18.2 Expression
Study Type: Treatment
Phase: I
NCTID: NCT05365581
Principal Investigator:
Anup Kasi
A Phase III, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Study Type: Treatment
Phase: III
NCTID: NCT07043400
Principal Investigator:
Raed Al-Rajabi
A Multicenter, Randomized, Open-Label, Phase III Trial of Trastuzumab Deruxtecan Enhertu� Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction GEJ Cancer Destiny-Gastric05
Study Type: Treatment
Phase: III
NCTID: NCT06731478
Principal Investigator:
Weijing Sun
Randomized Phase III Trial of Mfolfirnox +/- Nivolumab Vs. Folfox +/- Nivolumab for First-line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
Study Type: Treatment
Phase: III
NCTID: NCT05677490
Principal Investigator:
Gary Doolittle
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ? 1 Advanced Gastric and Esophageal Adenocarcinoma PARAMUNE
Study Type: Treatment
Phase: II/III
NCTID: NCT06203600
Principal Investigator:
Gary Doolittle